ClinicalTrials.gov
public full text
Public Domain
Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT as measured by the HHT Epistaxis Severity Score (ESS), hematocrit, and hemoglobin and serum ferritin levels.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Frequency of Common Medical Conditions in People With and Without HHT#801827
- Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, Bangladesh#918844
- Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age#805958
- A Study of TAK-279 in Healthy Chinese Adults#862752
- Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement#28467
Record · ID 1009029
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive